Monopar Therapeutics (MNPR) Competitors $37.58 -0.02 (-0.05%) Closing price 03/25/2025 04:00 PM EasternExtended Trading$37.99 +0.41 (+1.09%) As of 03/25/2025 06:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MNPR vs. OCS, CDMO, QURE, PRAX, AVXL, XERS, CMRX, ABCL, PRTA, and BCAXShould you be buying Monopar Therapeutics stock or one of its competitors? The main competitors of Monopar Therapeutics include Oculis (OCS), Avid Bioservices (CDMO), uniQure (QURE), Praxis Precision Medicines (PRAX), Anavex Life Sciences (AVXL), Xeris Biopharma (XERS), Chimerix (CMRX), AbCellera Biologics (ABCL), Prothena (PRTA), and Bicara Therapeutics (BCAX). These companies are all part of the "pharmaceutical products" industry. Monopar Therapeutics vs. Oculis Avid Bioservices uniQure Praxis Precision Medicines Anavex Life Sciences Xeris Biopharma Chimerix AbCellera Biologics Prothena Bicara Therapeutics Oculis (NASDAQ:OCS) and Monopar Therapeutics (NASDAQ:MNPR) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, media sentiment, valuation, risk and community ranking. Do insiders & institutionals believe in OCS or MNPR? 22.3% of Oculis shares are owned by institutional investors. Comparatively, 1.8% of Monopar Therapeutics shares are owned by institutional investors. 34.9% of Monopar Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the media prefer OCS or MNPR? In the previous week, Oculis had 3 more articles in the media than Monopar Therapeutics. MarketBeat recorded 9 mentions for Oculis and 6 mentions for Monopar Therapeutics. Oculis' average media sentiment score of 0.54 beat Monopar Therapeutics' score of 0.01 indicating that Oculis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oculis 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Monopar Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility & risk, OCS or MNPR? Oculis has a beta of 0.01, meaning that its share price is 99% less volatile than the S&P 500. Comparatively, Monopar Therapeutics has a beta of 1.18, meaning that its share price is 18% more volatile than the S&P 500. Do analysts prefer OCS or MNPR? Oculis presently has a consensus price target of $29.50, suggesting a potential upside of 49.90%. Monopar Therapeutics has a consensus price target of $44.00, suggesting a potential upside of 17.08%. Given Oculis' higher probable upside, analysts clearly believe Oculis is more favorable than Monopar Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oculis 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00Monopar Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is OCS or MNPR more profitable? Monopar Therapeutics has a net margin of 0.00% compared to Oculis' net margin of -8,043.28%. Oculis' return on equity of -71.31% beat Monopar Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Oculis-8,043.28% -71.31% -56.85% Monopar Therapeutics N/A -107.21%-87.57% Does the MarketBeat Community favor OCS or MNPR? Monopar Therapeutics received 14 more outperform votes than Oculis when rated by MarketBeat users. However, 91.18% of users gave Oculis an outperform vote while only 73.77% of users gave Monopar Therapeutics an outperform vote. CompanyUnderperformOutperformOculisOutperform Votes3191.18% Underperform Votes38.82%Monopar TherapeuticsOutperform Votes4573.77% Underperform Votes1626.23% Which has stronger earnings & valuation, OCS or MNPR? Monopar Therapeutics has lower revenue, but higher earnings than Oculis. Monopar Therapeutics is trading at a lower price-to-earnings ratio than Oculis, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOculis$980K876.80-$98.92M-$2.31-8.52Monopar TherapeuticsN/AN/A-$8.40M-$1.97-19.08 SummaryOculis beats Monopar Therapeutics on 9 of the 15 factors compared between the two stocks. Remove Ads Get Monopar Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MNPR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MNPR vs. The Competition Export to ExcelMetricMonopar TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$229.31M$6.99B$5.68B$8.32BDividend YieldN/A2.72%4.55%4.02%P/E Ratio-19.087.2324.5519.25Price / SalesN/A230.77395.7294.09Price / CashN/A65.6738.1634.64Price / Book19.996.617.064.46Net Income-$8.40M$142.13M$3.19B$247.07M7 Day Performance9.34%2.79%1.49%3.05%1 Month Performance20.80%2.70%5.87%-2.85%1 Year Performance958.59%-4.42%14.94%4.63% Monopar Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MNPRMonopar Therapeutics1.276 of 5 stars$37.58-0.1%$44.00+17.1%+958.6%$229.31MN/A-19.0810Upcoming EarningsGap DownOCSOculis2.5743 of 5 stars$18.83+0.3%$29.50+56.7%+69.7%$822.16M$980,000.00-9.762CDMOAvid Bioservices0.9963 of 5 stars$12.50+0.1%$12.25-2.0%+82.9%$799.18M$139.91M-5.23320High Trading VolumeQUREuniQure1.9348 of 5 stars$14.53+2.3%$38.89+167.6%+168.4%$785.74M$27.12M-2.93500News CoveragePRAXPraxis Precision Medicines2.917 of 5 stars$38.93+1.7%$123.80+218.0%-29.0%$784.95M$8.55M-3.78110AVXLAnavex Life Sciences3.9129 of 5 stars$9.20-2.4%$44.00+378.3%+110.1%$782.59MN/A-16.7340News CoverageXERSXeris Biopharma3.3134 of 5 stars$5.03+4.4%$5.92+17.6%+178.2%$774.32M$203.07M-11.18290High Trading VolumeCMRXChimerix2.8649 of 5 stars$8.47+0.1%$8.53+0.7%+764.4%$761.76M$159,000.00-9.0190Earnings ReportAnalyst ForecastABCLAbCellera Biologics2.6225 of 5 stars$2.54+0.8%$7.00+175.6%-44.8%$756.89M$28.83M-4.16500Positive NewsPRTAProthena2.9693 of 5 stars$13.74flat$55.00+300.3%-50.2%$739.58M$135.16M-5.97130Positive NewsBCAXBicara TherapeuticsN/A$13.50+8.7%$36.50+170.4%N/A$734.62MN/A0.0032Gap Down Remove Ads Related Companies and Tools Related Companies Oculis Alternatives Avid Bioservices Alternatives uniQure Alternatives Praxis Precision Medicines Alternatives Anavex Life Sciences Alternatives Xeris Biopharma Alternatives Chimerix Alternatives AbCellera Biologics Alternatives Prothena Alternatives Bicara Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MNPR) was last updated on 3/26/2025 by MarketBeat.com Staff From Our PartnersDOGE could send 6 AI stocks through the roofStay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement f...Weiss Ratings | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Monopar Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Monopar Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MNPR Stock Free MNPR Stock Alerts